Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Novartis boosts 2019 forecasts as Cosentyx, Zolgensma shine

      Novartis boosts 2019 forecasts as Cosentyx, Zolgensma shine

      Medical Dialogues Bureau27 Oct 2019 9:45 AM IST
      Zolgensma, the $2.1 million-per-patient treatment for spinal muscular atrophy, posted $160 million in sales. Novartis now anticipated approval in...
      Strides Pharma reports revenue of Rs 718 crore for Q2

      Strides Pharma reports revenue of Rs 718 crore for Q2

      Medical Dialogues Bureau27 Oct 2019 9:32 AM IST
      EBITDA margins stood at 21 per cent, up by 300 basis point quarter-on-quarter and 1,170 bps year-on-year. EBITDA margin expansion was led by good...
      Alexion Ultomiris gets USFDA approval for treating another rare blood disease

      Alexion Ultomiris gets USFDA approval for treating another rare blood disease

      Medical Dialogues Bureau27 Oct 2019 9:15 AM IST
      The treatment, Ultomiris, has already been approved in the United States, Japan and the European Union to treat adults with a blood disorder called...
      Biogen in consultation with USFDA plans regulatory filing for AD drug Aducanumab

      Biogen in consultation with USFDA plans regulatory filing for AD drug Aducanumab

      Medical Dialogues Bureau27 Oct 2019 9:00 AM IST
      New Delhi: Biogen and Eisai, Co., Ltd. (Tokyo, Japan) recently announced that, after consulting with the U.S. Food and Drug Administration (FDA),...
      Shilpa Medicare Telangana facility gets EIR from USFDA

      Shilpa Medicare Telangana facility gets EIR from USFDA

      Medical Dialogues Bureau26 Oct 2019 11:46 AM IST
      "The USFDA has concluded that the inspection classification of Jadcherla facility was "voluntary action indicated". This facility is in an acceptable...
      Aurobindo Pharma wins USFDA nod for generic version of Mucinex Tablets

      Aurobindo Pharma wins USFDA nod for generic version of Mucinex Tablets

      Medical Dialogues Bureau26 Oct 2019 10:00 AM IST
      Guaifenesin extended-release tablets are the generic version of RB Health (US) LLC's Mucinex tablets, Aurobindo Pharma said.New Delhi: Drug firm...
      AstraZeneca new drugs including Tagrisso, Lynparza boost Q3 product sales

      AstraZeneca new drugs including Tagrisso, Lynparza boost Q3 product sales

      Medical Dialogues Bureau26 Oct 2019 9:30 AM IST
      New Delhi: AstraZeneca Plc reported better-than-expected third-quarter product sales on Thursday, on the back of strong demand for newer medicines...
      Abbott, Australian Blood Service ink agreement for Alinity System

      Abbott, Australian Blood Service ink agreement for Alinity System

      Medical Dialogues Bureau26 Oct 2019 9:15 AM IST
      New Delhi: Abbott recently announced the Australian Red Cross Blood Service (Australian Blood Service) has signed a multiple-year agreement for...
      Crown Bioscience launches patient-derived tumour organoid drug development platform

      Crown Bioscience launches patient-derived tumour organoid drug development platform

      Medical Dialogues Bureau26 Oct 2019 9:00 AM IST
      New Delhi: Crown Bioscience recently announced the launch of a new tumour organoid drug development platform with the potential to significantly...
      Medical Devices classified as Drugs: CDSCO releases Amendment Rules for registeration of 36 devices

      Medical Devices classified as Drugs: CDSCO releases Amendment Rules for registeration of 36 devices

      Medical Dialogues Bureau25 Oct 2019 4:29 PM IST
      New Delhi: Through a recent Gazette Notification, Central Drugs Standard Control Organisation (CDSCO) has recently released Draft Medical Devices...
      Alembic Pharma JV gets USFDA approval for Desonide Ointment to treat skin diseases

      Alembic Pharma JV gets USFDA approval for Desonide Ointment to treat skin diseases

      Medical Dialogues Bureau25 Oct 2019 11:45 AM IST
      Desonide Ointment, 0.05 per cent, is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of...
      New batch of Strides Pharma Ranitidine available for sale in Australia

      New batch of Strides Pharma Ranitidine available for sale in Australia

      Medical Dialogues Bureau25 Oct 2019 11:33 AM IST
      Out of the 135 batches of Ranitidine which were tested by TGA, 109 batches were found to have an NDMA level at or above the acceptable limit of 0.3...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok